Humacyte HUMA
NASDAQ HUMA
$0.64 -0.04 (-5.75%)
At close: Aug 21, 2026 · 4:00 PM EDT

Humacyte (HUMA) Long-Term Debt Repayments (2025)

Humacyte (HUMA) posted quarterly Long-Term Debt Repayments of $50.0 million for Q3 2025.

Humacyte (HUMA) Long-Term Debt Repayments (2025) Analysis & Trends

Humacyte (HUMA) has reported Long-Term Debt Repayments for 1 consecutive years, with $50.0 million the latest figure, recorded in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 17.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -10.01 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Humacyte 150.77 Mn 150.77 Mn -825,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 50.00 Mn
Sep 30, 2025 50.00 Mn